Quince Therapeutics to Participate at Investor Events in January 2024

Rhea-AI Summary

Quince Therapeutics, a late-stage biotechnology company (Nasdaq: QNCX), announced that Dirk Thye, M.D., the CEO and CMO, will participate in two investor events in San Francisco in January 2024 to discuss innovative drug delivery technology for rare disease therapeutics.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San Francisco, California in January 2024:

• 7^th Annual Neuroscience Innovation Forum (NIF) – Sunday, January 7, 2024: Dr. Thye will participate in a panel discussion entitled “Exploring New Modalities for Rare & Orphan Neurological Diseases” from 11:00 a.m. to 12:00 p.m. Pacific Time and provide a company overview from 1:30 p.m. to 1:50 p.m. Pacific Time. Access to the NIF event is available to registered attendees only.

• Biotech Showcase™ 2024 – Tuesday, January 9, 2024: Dr. Thye will provide a company overview from 3:30 p.m. to 4:00 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104212468/en/

Media & Investor Contact:

Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

ir@quincetx.com

Source: Quince Therapeutics, Inc.

FAQ

What is the company name and ticker symbol mentioned in the press release?

The company mentioned in the press release is Quince Therapeutics, and its ticker symbol is QNCX.

What is the focus of Quince Therapeutics?

Quince Therapeutics is focused on developing an innovative drug delivery technology for rare disease therapeutics.

Who will participate in the investor events?

Dr. Dirk Thye, the CEO and CMO of Quince Therapeutics, will participate in the investor events.

Where and when will the events take place?

The events will take place in San Francisco, California in January 2024.

Will there be a live webcast of the presentation?

Yes, there will be a live webcast of the presentation accessible on Quince's Investor Relations website.

How can one access the NIF event?

Access to the NIF event is available to registered attendees only.

What will be discussed in the panel discussion at the NIF event?

The panel discussion will be about 'Exploring New Modalities for Rare & Orphan Neurological Diseases'.

Will there be an archive of the webcast available?

Yes, an archive of the webcast will be available shortly following the end of the live event.